<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	
	>
<channel>
	<title>
	Comments on: AI therapeutics announces start of Phase II Trial of LAM-002A (apilimod dimesylate) for treatment of COVID-19 patients	</title>
	<atom:link href="https://bioengineer.org/ai-therapeutics-announces-start-of-phase-ii-trial-of-lam-002a-apilimod-dimesylate-for-treatment-of-covid-19-patients/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org/ai-therapeutics-announces-start-of-phase-ii-trial-of-lam-002a-apilimod-dimesylate-for-treatment-of-covid-19-patients/</link>
	<description>Bioengineering</description>
	<lastBuildDate>Mon, 27 Jul 2020 14:02:41 +0000</lastBuildDate>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>
</channel>
</rss>
